Prana to present AD data at ICAD

Australia's Prana Biotechnology will present findings from a Phase IIa clinical trial during the "Hot Topics" session at the International Conference on Alzheimer's disease to be held in Chicago, USA, between July 27 and 30.

Jeffrey Cummings, the firm's R&D chairman, will be presenting a talk entitled Targeting Abeta as a Modifying Therapy of Alzheimer's Disease at the ICAD, which will include data from a Phase IIa trial of PBT2, an amyloid beta-42 peptide in development for treatment of AD.

The randomized, double-blind, placebo-controlled clinical trial was a 12-week study in mild AD patients. PBT2 demonstrated safety and tolerability, reduced Abeta 42 in the cerebrospinal fluid, and improved Executive Function performance in select cognitive tests, according to the company.